Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old

The Journal of Infectious Diseases
Debra L PalazziCarol J Baker

Abstract

One-third of the cases of invasive group B streptococcal (GBS) disease now occur in adults >or=65 years old. Serotype V is most frequent among these invasive isolates. The safety and immunogenicity of type V GBS capsular polysaccharide (CPS)-tetanus toxoid (V-TT) conjugate vaccine (CV) were assessed in 32 healthy adults 65-85 years old who were randomized to receive a single intramuscular dose of V-TT CV (n=22) or licensed tetanus-diphtheria toxoid vaccine (Td) (n=10; double-masked design). V-TT CV elicited significant increases in type V CPS-specific immunoglobulin (Ig) G, IgM, and IgA serum concentrations 4, 8, 26, and 52 weeks after immunization. V-TT-induced type V CPS-specific antibodies promoted the opsonophagocytic killing of type V GBS in vitro. Both vaccines elicited similar concentrations of TT-specific IgG in 4-week postimmunization serum samples. These results suggest the potential for prevention of invasive type V GBS infections in healthy elderly adults through immunization.

Citations

Aug 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Morven S Edwards, Carol J Baker
May 23, 2006·Infection and Immunity·Philipp Henneke, Reinhard Berner
Aug 11, 2010·The American Journal of the Medical Sciences·Michael S Bronze, James B Dale
Apr 20, 2010·Journal of the American Geriatrics Society·Kevin P HighKenneth E Schmader
Oct 22, 2016·Emerging Infectious Diseases·Morven S EdwardsImmaculada Margarit
Aug 20, 2015·Therapeutic Advances in Vaccines·Annalisa NuccitelliDomenico Maione
Aug 26, 2016·Journal of Clinical Microbiology·Miyuki MorozumiKimiko Ubukata
Apr 29, 2006·Current Opinion in Infectious Diseases·Sybille Kenzel, Philipp Henneke
Mar 1, 2008·Proteomics. Clinical Applications·Jason N ColeMark J Walker
May 14, 2005·Expert Review of Vaccines·Paul T Heath, Robert G Feldman
May 25, 2011·Expert Review of Vaccines·Paul T Heath
Nov 7, 2019·Human Vaccines & Immunotherapeutics·Min Joo ChoiJoon Young Song
Apr 25, 2018·Journal of Community Hospital Internal Medicine Perspectives·J Isaac Peña-GarciaAlexandre Lacasse
Sep 21, 2019·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Zefiryn CybulskiAndrzej Roszak
Mar 16, 2019·Microbiology Spectrum·Lawrence C Paoletti, Dennis L Kasper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.